10.6084/m9.figshare.11925636.v1 Craig Leonardi Craig Leonardi Kristian Reich Kristian Reich Peter Foley Peter Foley Hideshi Torii Hideshi Torii Sascha Gerdes Sascha Gerdes Lyn Guenther Lyn Guenther Melinda Gooderham Melinda Gooderham Laura Ferris Laura Ferris Christopher E.M. Griffiths Christopher E.M. Griffiths Hany Elmaraghy Hany Elmaraghy Heidi Crane Heidi Crane Himanshu Patel Himanshu Patel Russel Burge Russel Burge Gaia Gallo Gaia Gallo David Shrom David Shrom Ann Leung Ann Leung Cheng-Yen Lin Cheng-Yen Lin Kim Papp Kim Papp Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-To-Severe Psoriasis: Long-Term Results From the UNCOVER-1 and UNCOVER-2 Phase 3 Randomized Controlled Trials Adis Journals 2020 Ixekizumab Long-term efficacy Long-term safety Maintain Psoriasis Quality of life 5 years 2020-03-18 11:24:46 Figure https://adisjournals.figshare.com/articles/figure/Efficacy_and_Safety_of_Ixekizumab_Through_5_Years_in_Moderate-To-Severe_Psoriasis_Long-Term_Results_From_the_UNCOVER-1_and_UNCOVER-2_Phase_3_Randomized_Controlled_Trials/11925636 <p><strong>Provide enhanced digital features for this article</strong><br></p><p> This Figshare page contains a Summary Slide. If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact <u>adisrapidplus@springer.com</u>.<br> <br> The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.<br> <br> Other enhanced features include, but are not limited to:<br> • Slide decks<br> • Videos and animations<br> • Audio abstracts<br> • Audio slides</p>